Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder

Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

Colorado ,United States ,Pennsylvania ,Radnor ,Scott Braunstein ,Karen Utley ,Scott Demarest ,Us Drug Enforcement Administration ,Drug Enforcement Administration ,Drug Administration ,International Foundation ,Nasdaq ,Exchange Commission ,Marinus Pharmaceuticals ,University Of Colorado School Medicine ,Marinus Pharmaceuticals Inc ,Clinical Research Network ,Chief Executive Officer ,Principal Investigator ,Clinical Director ,Precision Medicine ,Research Network ,Assistant Professor ,Colorado School ,Priority Review ,Rare Pediatric Disease ,Rare Pediatric Disease Priority Review Voucher ,Fourth Quarter ,Antiepileptic Drugs ,Prescribing Information ,Private Securities Litigation Reform Act ,Enforcement Administration ,Resume ,Careers ,Arinus Pharmaceuticals Announces Fda Approval Of Ztalmy Ganaxolone For Cdkl5 Deficiency Disorder ,Iospace ,Advice ,